Management of hand-foot syndrome induced by capecitabine
- 2 September 2006
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 12 (3), 131-141
- https://doi.org/10.1177/1078155206069242
Abstract
Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to define the pathophysiology, risk factors, incidence and management of capecitabine-induced HFS. Methods. Literature for this review article was collected from the following databases: PubMed, CINAHL, and the proceedings of the American Society of Clinical Oncology (ASCO) confined to the years 1995-2006. The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda®, colorectal cancer, and metastatic breast cancer. Results. HFS associated with capecitabine is a serious dose-limiting toxicity. Incidence of grade 3/4 toxicity is of extreme significance, and introduces the need for dose reductions and/or interruptions in capecitabine therapy. Drug-related therapies studied include topical emollients and creams, systemic and topical corticosteroids, nicotine patch, vitamin E, pyridoxine, and COX-2 inhibitors. However, due to the lack of randomized, controlled trials with these therapies, the current mainstay of treatment for the management of this toxicity is interruption of therapy and, if necessary, dose reduction. Conclusion. Treatment interruption or dose reduction remain the only methods shown to effectively manage HFS, but supportive measures to reduce pain and discomfort and prevent secondary infection are very important. Many other prophylactic and treatment strategies have been investigated, with pyridoxine and COX-2 inhibitors being the most promising in case reports and retrospective studies; therefore, prospective, randomized, controlled trials are needed to prove their efficacy.Keywords
This publication has 41 references indexed in Scilit:
- Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group StudyJournal of Clinical Oncology, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Hand‐Foot Syndrome in Patients Treated With Capecitabine‐Containing Combination ChemotherapyThe Journal of Clinical Pharmacology, 2004
- Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabineJournal of Oncology Pharmacy Practice, 2003
- Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modificationEuropean Journal of Cancer, 2001
- Acral erythema induced by chemotherapy with cisplatinBritish Journal of Dermatology, 1998
- Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With TaxotereJNCI Journal of the National Cancer Institute, 1993
- Treatment of cytarabine acral erythema with corticosteroidsJournal of the American Academy of Dermatology, 1991